Eikon Therapeutics Raises $351 Million in Series D Round, Total VC Funds Reach $1.1 Billion for Cancer Drug Pipeline

Eikon Therapeutics has successfully raised $351 million in a Series D funding round, marking one of the largest biotech venture rounds of the year. The Hayward, California-based company, which specializes in developing cancer drugs, has now secured a total of $1.1 billion in venture capital since its inception in 2019. The latest funding will support its drug pipeline, notably EIK-1001, which is currently in late-stage testing for melanoma and continuing Phase II trials for non-small cell lung cancer. Eikon Therapeutics is also preparing for a potential public offering, positioning itself as the first Bay Area biotech company to do so this year. This funding round is seen as a significant boost for the company as it advances its innovative drug development efforts.